| HS Code | 269236 |
| Product Name | Mink Distemper Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Vaccine Type | Live attenuated viral vaccine |
| Target Species | Mink and other susceptible mustelids as directed by a veterinarian |
| Active Ingredient | Live attenuated canine distemper virus (CDV) strain |
| Primary Indication | Active immunization of mink against canine distemper |
| Veterinary Grade Api | Yes, suitable for veterinary pharmaceutical formulation |
| Dosage Forms Supported | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Route Of Administration | Subcutaneous, intramuscular, or oral depending on finished dosage form and veterinary protocol |
| Shelf Life | Typically 18 to 24 months when stored under recommended conditions |
| Solubility Or Dispersibility | Suspensible or soluble in appropriate sterile diluent; solid forms dispersible in feed, water, or excipients |
| Adverse Reactions | Mild transient lethargy, injection-site swelling, or fever; rare hypersensitivity reactions may occur |
| Withdrawal Period | No withdrawal period required when used according to label directions |
| Packaging | Bulk sterile containers or sealed vials appropriate for veterinary pharmaceutical processing |
| Production Standard | Manufactured under GMP conditions suitable for veterinary biological APIs |
As an accredited Mink Distemper Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 10 mL sterile glass vials with rubber stoppers and aluminum seals. Quantity: 50 vials per carton, cold-chain shipped. |
| Container Loading (20′ FCL) | 20′ FCL loading of live mink distemper vaccine (veterinary grade API) requires temperature-controlled, secure packing to maintain cold chain integrity. |
| Shipping | Shipping: Ship under strict cold chain at 2–8°C; do not freeze. Use validated insulated packaging with gel packs and temperature loggers. Transport via priority air freight, labeled as Biological Substance Category B (UN3373). Maintain temperature integrity throughout transit with clear handling documentation and immediate dispatch protocols. |
| Storage | Store at 2–8°C in a refrigerator. Protect from light, moisture, and freezing. Keep container tightly sealed. For tablets, capsules, powders, granules, premix, and solutions/suspensions, ensure sterility is maintained for injections. Do not mix with other vaccines until administration. Use immediately upon opening, per veterinary protocol. |
| Shelf Life | Shelf life: 24 months from manufacture when stored at 2–8°C, protected from light and moisture. Do not freeze. |
For the farmed mink sector in northern fur-producing regions, the live attenuated mink distemper antigen is incorporated into a lyophilized monovalent vaccine administered by subcutaneous injection; this presentation is the reference downstream use for the veterinary grade API. The formulation path is constrained by the thermolability of the enveloped RNA virus during freeze-drying and by the need to demonstrate extraneous agent freedom in the master seed lot under 9 CFR 113.306, with additional extraneous virus testing per Ph. Eur. 2.6.16 and mycoplasma testing per Ph. Eur. 2.6.7 when the dossier enters a European review. Target animal safety documentation is organised under VICH GL44, and the international reference for distemper vaccine quality remains OIE Terrestrial Manual Chapter 3.1.12. The active fraction is not expressed as a dry mass percentage; clarified cell culture harvest is diluted 1:1 with a 2× stabilizer concentrate, yielding final excipient concentrations of 5.0–10.0% w/v sucrose, 1.0–2.0% w/v hydrolyzed gelatin, and 0.5–1.0% w/v monosodium glutamate in phosphate-buffered saline at pH 7.2–7.4, while the virus content is adjusted to the target TCID50 per dose by titration rather than by a fixed volume fraction. The downstream production process starts with clarification of infected cell culture harvest through a 0.45 μm depth filter, followed by blending at 2–8°C, filling into Type I borosilicate glass vials at 0.5–1.0 mL per vial under Grade A laminar flow, and freeze-drying in a lyophilizer with shelf temperature ramp from −45°C to +25°C over 24–36 h. Primary drying endpoints are determined by capacitance manometer and Pirani gauge divergence, and cakes are released only when residual moisture by Karl Fischer titration is ≤3.0%. The terminal finished product type is a single-dose or 10-dose lyophilized cake in a Type I vial sealed with a butyl rubber stopper and aluminium cap, reconstituted to 1.0 mL per subcutaneous dose. The table below summarises the stabilizer window and the associated drying constraint for each component.
| Stabilizer component | Addition ratio | Function | Primary process constraint |
|---|---|---|---|
| Sucrose | 5.0–10.0% w/v | glass-forming protectant | collapse if shelf temperature exceeds cake glass transition |
| Hydrolyzed gelatin | 1.0–2.0% w/v | bulking agent and cryoprotectant | excessive concentration raises reconstitution viscosity |
| Monosodium glutamate | 0.5–1.0% w/v | enveloped virus stabilizer | pH shift during thawing must be controlled |
| Phosphate-buffered saline | q.s. ad 1.0 mL | isotonic carrier | ionic strength influences virus aggregation |
The live attenuated enveloped virus used in mink distemper vaccines is not present in any 9 CFR 113.306-licensed tablet, capsule, granule, or feed premix product, and neither Ph. Eur. nor VICH provides a monograph or guideline defining a solid oral dosage form for this biological API. The absence of a compendial addition ratio is matched by the physical and physiological incompatibility of live virus with solid oral processing: conventional dry granulation binder addition at 1–5% w/w followed by tablet compression at >50 MPa is associated with live virus infectivity loss of more than 2 log10 TCID50 in studies of comparable enveloped RNA viruses, and the gastric acid environment at pH <3.0 would further inactivate any antigen that survived tableting. The downstream production process for such a dosage form would require lyophilized cake milling under <10% relative humidity, dry blending with a cryogenic excipient system, and tablet compression or capsule filling, but these operations have no validated potency release test for live virus after compaction and no batch-release standard for antigen integrity. The terminal finished product type would be a tablet, hard gelatin capsule, granule, or feed premix; no such licensed terminal product exists for the live mink distemper antigen, and published data for this specific configuration is limited. Procurement specifications should therefore restrict the raw material to parenteral liquid or lyophilized presentations and reject any solid oral-form claim as non-compliant with current veterinary biological product standards.
Where mink farms operate integrated breeding and pelting cycles, vaccination labour is often consolidated into a single bivalent injection; the live distemper API is paired with an inactivated mink enteritis virus fraction to generate a combined product. The distemper component is released under 9 CFR 113.306, and the mink enteritis component is released under 9 CFR 113.304; mutual interference testing in the target species is required, and final batch release includes moisture content, sterility, live virus titration, and inactivation control on the killed fraction. The addition ratio for the live antigen in this bivalent configuration is set by potency rather than dry mass: clarified live distemper harvest is added at 20–40% v/v into a stabilised bulk containing 5.0% w/v sucrose, 1.5% w/v hydrolyzed gelatin, and 2.0% w/v sorbitol, and the inactivated mink enteritis diluent is adjusted to 0.5–1.0 mg Al3+ per dose as aluminium hydroxide adjuvant. The downstream production process keeps the live and inactivated antigen streams segregated until final assembly: the live distemper bulk is clarified, blended at 2–8°C, filled into Type I vials, and lyophilized under the drying conditions described for the monovalent product; the inactivated enteritis component is prepared in a separate filling line as a liquid diluent and filled into 1.0 mL Type I vials or ampoules; the two components are then paired in a single carton. The terminal finished product type is a bivalent vaccine consisting of a live distemper lyophilized cake for reconstitution with a liquid diluent containing killed mink enteritis fraction, administered as 1.0 mL subcutaneously.
A frozen liquid presentation of the live distemper antigen is occasionally requested by large farmed mink production units that run automatic syringes or needle-free injection equipment. This presentation is not available in every jurisdiction; published data for this specific configuration is limited, and any supplier change should be justified by a comparability protocol. The applicable compliance framework remains 9 CFR 113.306 for live distemper potency and extraneous agent freedom, with additional container-closure integrity evaluation at −20°C and real-time stability data for the liquid frozen state. The formulation addition ratio uses the same 1:1 dilution approach with a 2× stabilizer concentrate, yielding final concentrations of 5.0–10.0% w/v sucrose and 1.0–2.0% w/v hydrolyzed gelatin in phosphate-buffered saline; the antigen is adjusted to the same target TCID50 per dose as the lyophilized product. The downstream production process is shorter than the lyophilized route because it omits freeze-drying: harvest is clarified through a 0.45 μm depth filter, stabilised, filled into 10–50 mL Type I vials, and frozen at −20°C or below under controlled-rate freezing. The terminal finished product type is a frozen liquid veterinary vaccine vial intended for thawing at 2–8°C and administration through a multi-dose or automatic injection device; once thawed, the product must be used within the validated in-use holding period.
Oral bait delivery of live attenuated mink distemper antigen has been evaluated in research settings where parenteral administration is impossible, but it is not a licensed commercial presentation. The regulatory framework for experimental use includes a national competent authority permit, target animal safety testing under VICH GL44, and consistency with the extraneous agent requirements of Ph. Eur. 2.6.16; no standard potency monograph for an oral bait dosage form exists. The formulation addition ratio reported in published research resuspends lyophilized antigen in phosphate-buffered saline containing 5.0% w/v sucrose to a titre of 10^5.0–10^6.0 TCID50 per mL, and 0.5 mL of the suspension is added to 2.0 g of a lipid-based bait matrix; published data for this specific configuration is limited, and the virus titre after extrusion and freezing must be pre-tested for each batch. The downstream production process uses low-shear mixing at 2–8°C, extrusion into 1.5–2.0 g bait sachets, and flash-freezing at −80°C to preserve infectivity. The terminal finished product type is a frozen oral bait sachet intended for research or emergency wildlife vaccination; it is not a farmed mink commercial product and should not be substituted for the registered injectable presentation.
Diluent compatibility and two-vial kit assembly are downstream finishing steps that convert the lyophilized monovalent or bivalent cake into a usable field vaccine; the diluent itself does not contain live mink distemper antigen, and its addition ratio is therefore 0% v/v API. The diluent is typically sterile water for injections conforming to Ph. Eur. 0169 or the equivalent national monograph, with sodium chloride 0.9% w/v in phosphate-buffered presentations; visible particulate matter is controlled under Ph. Eur. 2.9.20, and osmolality is held at 280–320 mOsm/kg to avoid osmotic shock after reconstitution. The downstream production process includes water-for-injection generation, 0.22 μm sterilising filtration, filling into Type I glass vials or sterile plastic ampoules, and terminal steam sterilisation at 121°C for 15 min; the diluent filling line is segregated from the live antigen filling suite to prevent cross-contamination. The terminal finished product type is a two-vial kit consisting of a lyophilized live distemper cake and a companion diluent vial, reconstituted to 1.0 mL per subcutaneous dose immediately before administration; the assembled kit must pass container-closure integrity and label-copy verification before release.
Competitive Mink Distemper Vaccine,Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Mink Distemper Vaccine, Live Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a bulk lyophilized live attenuated canine distemper virus antigen intended solely for further manufacture into finished veterinary immunological dosage forms. The material is not a retail finished vaccine and must not be administered directly without potency adjustment, formulation, and regulatory release. Manufacturer-assigned model codes typically encode the virus seed lineage, stabilizer matrix, and freeze-drying cycle; no harmonized model numbering system exists across licensing jurisdictions. The active substance is produced from clarified infectious cell culture fluid blended with a protective matrix of buffering agents, saccharides, and hydrolyzed protein or amino acid stabilizers, then freeze-dried to a residual moisture content normally maintained below 3.0%. The resulting powder or plug is intended to retain sufficient live virus infectivity for downstream processing into tablets, injectable lyophilisates, capsules, powders, granules, premixes, or reconstitutable solutions. The antigen targets canine distemper virus in mink, a high-consequence morbillivirus infection associated with respiratory, gastrointestinal, neurological, and dermatological syndromes. Because the live viral antigen is thermolabile and acid-labile, every downstream unit operation must preserve infectivity; exposure to heat above 25 °C, acidic pH below 5.0, alkaline pH above 8.0, or high-shear mixing can reduce the viable titre and compromise finished-product potency.
Analytical control of the live antigen bulk is normally aligned with the European Pharmacopoeia monograph 0451 for live canine distemper vaccine, the relevant chapter of the OIE Terrestrial Manual, and 9 CFR 113.306 where finished product is licensed in the United States. No mink-specific pharmacopoeial monograph exists for this active antigen; therefore the manufacturer’s licensing file defines the exact release limits, safety testing, and process validation data. Representative acceptance criteria are summarized in Table 1.
| Parameter | Typical acceptance criterion | Reference method or standard |
|---|---|---|
| Appearance | White to off-white lyophilized plug or powder | Visual inspection; manufacturer standard |
| Identity | Canine distemper virus-specific cytopathic effect and immunofluorescence | OIE Terrestrial Manual, CDV chapter |
| Bulk virus titre | ≥106.5 TCID50/mL before lyophilization | Vero cell titration, Spearman-Kärber or Reed-Muench calculation |
| Finished dose titre | 103.0–105.0 TCID50 per unit after reconstitution | 9 CFR 113.306; Ph. Eur. 0451 |
| Residual moisture | ≤3.0% | Karl Fischer titration, Ph. Eur. 2.5.12 |
| Sterility of bulk | No growth | Ph. Eur. 2.6.1; 9 CFR 113.26 |
| Mycoplasma | Negative | Ph. Eur. 2.6.7 |
| Bacterial endotoxin | ≤1 EU per dose | Ph. Eur. 2.6.14 |
| Safety in mink | No serious adverse reaction after 14-day observation | 9 CFR 113.306; manufacturer protocol |
The bulk titre of ≥106.5 TCID50/mL is typically required to allow for losses during blending, tableting, capsule filling, or freeze-drying and still achieve a finished dose titre of 103.0–105.0 TCID50 per unit. Downstream processing does not add infectivity and may reduce it by 0.5–2.0 log10 TCID50 depending on shear, temperature, and excipient interactions. Residual moisture is critical because excess water in the amorphous stabilizer matrix can lower the glass transition temperature and accelerate virus inactivation during storage.
For dry dosage forms, the lyophilized antigen bulk is blended with directly compressible excipients such as microcrystalline cellulose, lactose monohydrate, mannitol, or pregelatinized starch. Direct compression is preferred over wet granulation because aqueous granulation would reconstitute the virus and expose it to thermal stress during drying. However, direct compression imposes shear and compaction heat. Rotary tablet presses must be operated at reduced turret speed and controlled compaction force. Compression force above 10 kN may generate localized temperature and shear sufficient to inactivate enveloped live virus; the exact threshold depends on matrix composition, tooling size, and press speed. Formulation studies usually target tablet hardness of 20–50 N and friability below 1.0% according to Ph. Eur. 2.9.7 to balance mechanical integrity with virus survival. Published data for this specific mink distemper configuration are limited, so process feasibility must be confirmed by measuring virus titre loss at each compaction step.
Lubricant selection influences titre retention and tablet performance. Magnesium stearate concentrations above 1.0 wt% are generally avoided because hydrophobic films can delay disintegration and may not support long-term live virus stability. Sodium stearyl fumarate at 0.5–1.5 wt% or stearic acid at 0.5–1.0 wt% may be used as alternative lubricants. Disintegrants such as crospovidone or sodium starch glycolate at 2–5 wt% support rapid release in aqueous media, but if the tablet is intended for enteric protection, film coating with a pH-sensitive methacrylic acid copolymer is required. Coating pan inlet temperature must remain below 30 °C to avoid virus inactivation, and the coating dispersion must not contain solvent residues that are virucidal to the enveloped morbillivirus.
Oral delivery of live distemper virus to mink is not a simple substitution for parenteral injection. Gastric acid below pH 3.0 and intestinal bile salts can reduce infectivity by several log10 within minutes. Tablets, capsules, powders, granules, and premixes intended for oral administration therefore require acid protection or are positioned as booster formats after parenteral priming. Regulatory authorities generally require separate efficacy and shedding data for oral or mucosal routes before such claims can be approved.
For injectable finished products, the freeze-dried API is reconstituted in sterile diluent immediately before use. The reconstitution volume is fixed to achieve the target dose volume, commonly 1.0 mL per mink, with post-reconstitution titre adjusted to 103.0–105.0 TCID50 per dose. Stabilized diluents containing phosphate-buffered saline, sucrose, and hydrolyzed gelatin improve short-term thermal stability; water for injection alone is usually insufficient for prolonged holding. After reconstitution, the solution should be used within 2 hours and held at 2–8 °C. Exposure to room temperature beyond 1 hour is a common operational limit because live morbillivirus infectivity declines in liquid medium. Needles, syringes, and transfer lines must be free of disinfectant residues, particularly alcohol and quaternary ammonium compounds, because these agents are virucidal for enveloped viruses.
Liquid oral solutions and drinking-water premixes face additional stability challenges. Chlorine residuals in drinking water above 0.5 ppm or pH below 5.0 can inactivate the live virus before ingestion. Water for oral delivery should therefore be conditioned, and the vaccine solution should be dispersed in a stabilizer solution rather than directly in municipal water. Powder and granule premixes intended for feed must be mixed in a non-heated ribbon mixer, V-blender, or bin blender. The mixer jacket should remain below 25 °C, and the blend should be discharged within 30–60 minutes to limit moisture uptake. For capsules, automatic capsule filling machines generate limited shear but require low relative humidity below 35% RH to avoid stickiness of hygroscopic stabilizers.
The bulk lyophilized API is typically stored at -20 °C or below for long-term stability. Storage at 2–8 °C may be acceptable only for short periods defined in the manufacturer’s stability protocol. If the product is exposed to repeated freeze-thaw cycles, the amorphous stabilizer matrix may undergo phase separation and crystallization, reducing virus protection. Temperature excursions above 25 °C for more than 24 hours are generally considered a major deviation for live distemper antigen because thermal inactivation follows first-order kinetics with accelerated loss above the glass transition temperature. The residual moisture content below 3.0% is critical; at higher moisture levels, the glass transition temperature of sucrose-based matrices can fall below storage temperature, allowing molecular mobility and virus degradation. Manufacturers typically conduct accelerated stability studies at 25 °C and 37 °C to support cold-chain limits; published stability data for this exact mink API are limited.
During dry blending, the API is mixed with excipients in a bin blender or V-blender at low speed, typically 25 rpm for 10–15 minutes. High-shear granulators are not used because shear and temperature increase of 5–10 °C can cause measurable titre loss. The blend is then compressed or filled under controlled relative humidity, generally below 40% RH. If tablet compression is performed, the die bore and press speed should be optimized so that dwell time is short. Excessive heat from prolonged compression can reduce titre. In-process hold times between blending and tableting should be validated because moisture uptake from the ambient environment can increase water activity in the stabilizer matrix and accelerate virus inactivation.
Compared with inactivated mink distemper vaccines, the live attenuated API offers a different immunological profile and a different manufacturing risk profile. Inactivated vaccines require higher antigen mass, usually with an adjuvant, and are often limited to intramuscular or subcutaneous injection. Live attenuated vaccines replicate in the host, eliciting mucosal and cell-mediated immunity after a single dose in many protocols. The live API is supplied as a freeze-dried bulk without adjuvant, which permits formulation into a wider range of dosage forms, but it imposes stricter cold-chain and processing limits. Table 2 summarizes the principal comparative distinctions.
| Attribute | Live attenuated Mink Distemper API | Inactivated Mink Distemper Vaccine | Recombinant vector or subunit antigen |
|---|---|---|---|
| Antigen mass per dose | Replicates in host; low input titre required, 103.0–105.0 TCID50 | High antigen mass required; often concentrated | Fixed protein, plasmid, or vector dose |
| Dosage form flexibility | Freeze-dried bulk for tablets, injections, capsules, powders, granules, premixes, solutions | Typically aqueous suspension for injection | Usually injectable or oral vector; limited dry forms |
| Adjuvant requirement | Not required; replication enhances immunogenicity | Usually requires adjuvant such as aluminium hydroxide | May require adjuvant or may be limited by pre-existing vector immunity |
| Cold chain | Frozen bulk storage; refrigerated finished product | Refrigerated liquid, comparatively robust | Refrigerated or room-temperature depending on platform |
| Onset and duration | Rapid onset after 7–14 days; long duration due to cell-mediated memory | Slower onset; booster often required | Variable; maternally derived antibody or vector immunity may interfere |
| Manufacturing complexity | Live virus propagation, freeze-drying, titre maintenance | Inactivation and concentration; simpler biosafety profile | Recombinant expression, purification, vector containment |
These differences do not indicate universal superiority. The live antigen bulk is not appropriate for all production sites because it requires live-virus containment, dedicated lyophilization capacity, and titre-loss validation. A finished-product manufacturer cannot exchange an inactivated antigen for the live API in an existing formula without revalidating every downstream unit operation.
When a formulation developer replaces an inactivated antigen with the live attenuated mink distemper API in an injectable or oral finished product, the downstream process must be revalidated. The live virus cannot be terminally sterilized by autoclaving, gamma irradiation, or ethylene oxide. All components contacting the API after virus harvest must be sterile-filtered or steam-sterilized before aseptic blending. The filling line must operate under Grade A laminar flow with Grade B background according to EU GMP Annex 1 or ISO 14644-1 class ISO 5 conditions. Residual disinfectants used in line cleaning must be completely removed and verified because quaternary ammonium compounds, aldehydes, and alcohols are virucidal to enveloped virus at contact times as short as 30 seconds. The API cannot be exposed to steam or dry heat; therefore, equipment that cannot be sterilized in place or adequately freed of disinfectant residues must be isolated from the live antigen stream.
Clarified virus bulk may be filtered through a 0.45 µm membrane, but a 0.22 µm sterilizing filter is not recommended for live morbillivirus because the particle size is approximately 150–300 nm and filtration may remove or damage infectious particles. Use of a 0.45 µm pre-filter is acceptable; final sterility claims rely on aseptic processing rather than terminal filtration. The virus titre must be assayed after any filtration step to confirm that the process has not created unacceptable infectivity loss.
Because the API contains live attenuated virus, mink vaccinated with the finished product may shed vaccine virus in nasal secretions, saliva, and faeces for a limited period, typically 7–14 days after administration. The manufacturer must evaluate reversion-to-virulence potential in the target species and in susceptible non-target species. Safety tests in mink should include an overdose study at 10× the recommended dose in the target age group, observed for 14 days. Breeding females may require a separate reproductive safety evaluation. The live API is not recommended for use in immunocompromised mink, pregnant females unless specifically licensed, or mink concurrently treated with immunosuppressive doses of corticosteroids. Accidental self-injection by operators requires post-exposure medical evaluation because canine distemper virus is antigenically related to measles virus, although mink-adapted vaccine strains are not licensed for human use. Contaminated materials, reconstituted vaccine, and expired API should be chemically inactivated with 1% sodium hypochlorite or autoclaved at 121 °C for 30 minutes before disposal. Releases to water should be avoided because live morbillivirus may persist in organic debris even after chlorination.
